MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
2. Industry_Business Architects & Consolidators
Industry: By Region (Globally)
Industry: International
Industry: West + Pacific Rim
*Industry: Southern California
Evolus, Inc. (NASDAQ: EOLS)*
Organization & Developments: Evolus
Parents
Evolus, Inc. (NASDAQ: EOLS)*
Children
*FDA has approved Jeuveau for the temporary improvement in the appearance of moderate to severe glabellar lines.
2019: Evolus Gains FDA Approval For Treatment Of Frown Lines, Set To Rival Allergan_seekingalpha.com
2019: Evolus: Recently Approved Jeuveau A Direct Threat To Botox_seekingalpha.com
2021: Evolus: Surviving A Challenging Year
2021: Revisiting Evolus
2022: Evolus: Turning That Frown Upside Down_seekingalpha.com
2024: Evolus, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028
2024: Evolus's SWOT analysis: aesthetics firm's stock poised for growth
2025: Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
2025: Evolus: Still Bullish, But Business Faces Tricky Challenges In '25
Jumps
*Key People: Evolus
Finance & Acquisitions: Evolus